Sales of plasma products have grown by 8.2% at constant currency, reaching 184.6 million euros in the first quarter of 2010 and driving the group’s turnover.

- Grifols’ total income rose by 3.1% on a like for like basis (0.9% after allowing for the exchange rate effect) and stands at 237.7 million euros for the first three months of the year. Over 75% of revenues are generated outside Spain.

- The performance of the dollar against the euro and the planned reduction in sales by the Raw Materials Division explain the moderate growth in turnover. Excluding this division’s activity, the group’s growth was 7.1% at constant currency (4.8% after taking into account the effect of exchange rates).

- The EBITDA margin has risen to 30.3% over sales compared to 29.1% in 2009. EBITDA for the first quarter is 72.1 million euros.

- Net profit of 36.5 million euros is down 12.2% due to the rise in financial expenses as a result of additional funding raised in 2009.

Barcelona, April 28, 2010. - The Bioscience division has been the principal driver of the group’s income. Sales of plasma products rose by 5.3% during the first three months of the year, reaching 184.6 million euros, representing growth of 8.2% at constant currency. There was a particularly significant increase in demand for albumin in the context of stable prices, and for intravenous immunoglobulin (IVIG), primarily in the United States, where Grifols has increased its market share.

Sales of the Diagnostic division have also risen. They grew by 5.5% compared to the same period for 2009, standing at 27.3 million euros, thanks to steadily rising sales of reagent cards. The Hospital division’s sales have remained at levels similar to those recorded for the first quarter of 2009, totalling 21.9 million euros as a result of lower public and private investment in hospital automation systems in Spain due to the rationalisation of health expenditure. Finally, the Raw Materials division recorded turnover of approximately 4 million euros for sales of raw materials and other income which, compared to the 12.6 million euros for the same period of 2009, represents a significant reduction, as expected.

In overall terms, Grifols’ turnover during the first quarter of 2010 stood at 237.7 million euros, an increase of 0.9% compared to the same period of 2009. As had already been seen in the final quarter of 2009, the performance of the dollar against the euro had a
slight negative impact on income, given that, without the impact of exchange rate variations, growth would have been 3.1%.

Grifols has maintained its cost control policy during the first three months of the year. This together with sales performance and exchange rate fluctuations has resulted in an **EBITDA margin** of 30.3%, representing an improvement of 380 base points compared to the final quarter of the previous year, with no significant change compared to the same period of 2009. As a result, gross operating profit stood at **72.1 million euros**, a similar level to the figures for the previous year.

The additional new financial resources raised during 2009 led to an increase in financial expenses. These will continue to have an impact on the company’s net profits in following quarters. To March 2010 the accumulated **net profit** was 36.5 million euros, a fall of 12.2% compared to 2009.

Grifols **net financial debt** in the first three months of 2010 stood at 609.7 million euros, a ratio of 2.3 times EBITDA, similar to that recorded for the same period of the previous year and reflecting the solidity of the company’s balance sheet.

**Grifols rebalances geographical distribution of its sales. Turnover in emerging markets has risen by 41.0%, and market share in the United States continues to grow**

During this quarter, Grifols maintained its geographic diversification strategy, with the dual objective of consolidating sales of plasma products in regions such as Latin America and Asia-Pacific and changing the balance of the group’s income so that the relative importance of these regions grows, to take its place alongside the United States and Europe. The plan aims to build upon the growth forecast for the industry over the next few years as a result of the emergence of new plasma product markets. This trend also applies to the products and services marketed by the Diagnostic division.

From January to March 2010, excluding raw material division, sales in Europe reached 105.8 million euros, representing 44.5% of the group’s total income. In the United States, where Grifols has increased its market share, turnover stood at 70.7 million euros, a figure which represents 29.7% of turnover, while other geographic regions, including Brazil, Mexico, Argentina, China and Australia, generated 24.1% of sales and growth of 39.3% compared to the first quarter of 2009. In comparison to the fourth quarter of 2009, total sales increased by 6.3%.

Grifols is therefore promoting balanced growth to reflect the global plasma products market, in which North America accounts for approximately 37% of sales, Europe 31% and areas such as Japan, Latin America and Asia-Pacific taken together represent 27%.\(^1\) Demand remains strong in all of these regions.

In addition, Grifols expects that the health reforms recently approved by the United States Government will have a positive impact on the group by increasing the population which obtains basic health coverage, including coverage for pharmaceuticals. Increased Medicaid rebates, additional taxes, and foreseeable modifications under the Legislation for the calculation of reference prices could have a

---

\(^1\) Approximate data for the global plasma products market in 2008 from The Marketing Research Bureau (MRB) and company estimates
negative impact of approximately 1.2 million dollars annually. Additionally, Grifols does not expect these legislative changes to lead to an increase in the cost of providing health coverage for its employees in the United States.

First quarter 2010 figures

<table>
<thead>
<tr>
<th></th>
<th>Q1 2010</th>
<th>Q1 2009</th>
<th>% / 2009 2010</th>
<th>% 2010 / 2009 at constant currency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total revenue</td>
<td>237.7</td>
<td>235.6</td>
<td>+0.9%</td>
<td>+3.1%</td>
</tr>
<tr>
<td>Bioscience Division</td>
<td>184.6</td>
<td>175.3</td>
<td>+5.3%</td>
<td>+8.2%</td>
</tr>
<tr>
<td>Diagnostic Division</td>
<td>27.3</td>
<td>25.8</td>
<td>+5.5%</td>
<td>+5.7%</td>
</tr>
<tr>
<td>Hospital Division</td>
<td>21.9</td>
<td>21.9</td>
<td>-0.1%</td>
<td>-0.1%</td>
</tr>
<tr>
<td>Raw Materials</td>
<td>3.9</td>
<td>12.6</td>
<td>-68.4%</td>
<td>-67.9%</td>
</tr>
<tr>
<td>EBITDA</td>
<td>72.1</td>
<td>72.3</td>
<td>-0.3%</td>
<td></td>
</tr>
<tr>
<td>Net profit margin</td>
<td>30.3%</td>
<td>30.7%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net profit</td>
<td>36.5</td>
<td>41.6</td>
<td>-12.2%</td>
<td></td>
</tr>
<tr>
<td>Net profit margin</td>
<td>15.4%</td>
<td>17.7%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Key events during the quarter

The actions taken throughout the first quarter of 2010 have enabled Grifols to continue to strengthen its key business areas:

- **Grifols to construct new Spanish plant for Portuguese pharmaceuticals Bial**
  Grifols Engineering has won the tender for the construction and development of Bial’s new plant in Spain. The project has a total budget of 10 million euros, an extension of 5,000 square meters, and it is scheduled for completion in September 2011.

- **Grifols introduces holographic seal for plasma product containers to increase safety levels**
  The introduction of a holographic seal on the opening flap of containers is yet one more measure among many taken by Grifols in its commitment to ensure that its products enjoy the highest levels of safety, and to act as a guarantee for patients and health professionals.

- **Investment continues according to plan**
  During the first quarter of 2010 the group continued its scheduled investment plans, to ensure the medium-term completion of the new production plant for *Flebogamma® DIF* (IVIG) in the United States and the fibrin glue manufacturing plant in Spain (Barcelona), among others.
About Grifols

Grifols is a Spanish holding company specialized in the pharmaceutical-hospital sector and is present in more than 90 countries. Since 2006, the company has been listed on the Spanish Stock Exchange (“Mercado Continuo”) and is part of the Ibex-35. Currently it is the first company in the European sector in plasma derivatives and the fourth in production worldwide. In upcoming years, the company will strengthen its leadership in the industry as a vertically integrated company, thanks to recent investments. In terms of raw materials, Grifols has ensured its plasma supply with 80 plasmapheresis centers in the United States and in terms of fractionation, its plants in Barcelona (Spain) and Los Angeles (United States) will allow the company to respond to the growing market demand. Nevertheless, the company is preparing for sustained growth in the following 8-10 years and has launched an ambitious investment plan.